Caspase-mediated truncation of tau is associated with aggregation. We examined the impact of manipulation of caspase activity on intracellular aggregation of a mutant form of tau (3PO) that forms spontaneous aggregates. Treatment with the caspase inhibitor Z-VAD-fmk reduced both N and C-terminal tau truncation but did not significantly reduce aggregation. Treatment with staurosporine, which activated caspases, increased C-terminal but not N-terminal truncation and enhanced aggregation. These findings suggest that caspase activation is one potential route, rather than an obligatory initiation step, in aggregation, and that N- and C-terminal truncation contribute differentially to aggregation. One pathological hallmark of tauopathies is aggregation of the microtubule-associated protein tau. A growing body of evidence highlights the importance of truncation in initiation and potentiation of tau aggregation [1–8]. Tau truncated at amino acid D421 has been detected in Alzheimer’s disease (AD) [3, 4, 9, 10] and other tauopathies [11]. C-terminal truncation of tau introduces a conformational change, along with phosphorylation, contributes to aggregation [12–14]. Caspases are serine-aspartyl proteases typically considered to be activated during apoptosis, but can also be activated without apoptosis [15]. In this regard, while caspase activation precedes and promotes tangle formation [1], tangle-bearing neurons can survive for extended periods [16, 17]. Cleavage of tau at D421 has been suggested to be mediated by caspase-3 [3, 4]. By contrast, analyses of transgenic mice suggest that caspase-6, rather than caspase-3, may truncate tau at D421 [8]. Additional analyses in mice suggest that caspase activation may not be obligatory for tangle initiation, but rather may represent one of multiple mechanisms contributing to tau aggregation [18]. Truncation of tau at D13, which can also be mediated by caspase-6 [19], has been detected in AD brains [20]. Whether caspase-6 mediates this cleavage in situ is unclear [20, 21]. Any role for N-terminal cleavage in aggregation remains to be elucidated. Herein, we present evidence that tau truncation at D421 is not necessarily mediated by caspase-3 and that neither N- nor C- terminal truncation is essential for aggregation. NB2a/d1 cells were cultured and transfected as described [22] with a plasmid expressing GFP (Green Fluorescent Protein) tagged 3?PO tau, a mutated form of human tau that spontaneously aggregates but retains its microtubule binding capacity (gift of Dr. F. S. Wouters, Max-Planck-Institute, Germany) [23]. Medium
References
[1]
A. de Calignon, L. M. Fox, R. Pitstick et al., “Caspase activation precedes and leads to tangles,” Nature, vol. 464, no. 7292, pp. 1201–1204, 2010.
[2]
M. Novak, J. Kabat, and C. M. Wischik, “Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament,” The EMBO Journal, vol. 12, no. 1, pp. 365–370, 1993.
[3]
T. C. Gamblin, F. Chen, A. Zambrano et al., “Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 17, pp. 10032–10037, 2003.
[4]
R. A. Rissman, W. W. Poon, M. Blurton-Jones et al., “Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology,” Journal of Clinical Investigation, vol. 114, no. 1, pp. 121–130, 2004.
[5]
H. Ding, T. A. Matthews, and G. V. W. Johnson, “Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation,” Journal of Biological Chemistry, vol. 281, no. 28, pp. 19107–19114, 2006.
[6]
M. Pevalova, P. Filipcik, M. Novak, J. Avila, and K. Iqbal, “Post-translational modifications of tau protein,” Bratislavské Lekárske Listy, vol. 107, no. 9-10, pp. 346–353, 2006.
[7]
P. Delobel, I. Lavenir, G. Fraser et al., “Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy,” American Journal of Pathology, vol. 172, no. 1, pp. 123–131, 2008.
[8]
Q. Zhang, X. Zhang, J. Chen, Y. Miao, and A. Sun, “Role of caspase-3 in tau truncation at D421 is restricted in transgenic mouse models for tauopathies,” Journal of Neurochemistry, vol. 109, no. 2, pp. 476–484, 2009.
[9]
G. Basurto-Islas, J. Luna-Mu?oz, A. L. Guillozet-Bongaarts, L. I. Binder, R. Mena, and F. García-Sierra, “Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer's disease,” Journal of Neuropathology and Experimental Neurology, vol. 67, no. 5, pp. 470–483, 2008.
[10]
A. L. Guillozet-Bongaarts, F. Garcia-Sierra, M. R. Reynolds et al., “Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease,” Neurobiology of Aging, vol. 26, no. 7, pp. 1015–1022, 2005.
[11]
A. L. Guillozet-Bongaarts, K. E. Glajch, E. G. Libson et al., “Phosphorylation and cleavage of tau in non-AD tauopathies,” Acta Neuropathologica, vol. 113, no. 5, pp. 513–520, 2007.
[12]
L. I. Binder, A. L. Guillozet-Bongaarts, F. Garcia-Sierra, and R. W. Berry, “Tau, tangles, and Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1739, no. 2, pp. 216–223, 2005.
[13]
G. Carmel, E. M. Mager, L. I. Binder, and J. Kuret, “The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology,” Journal of Biological Chemistry, vol. 271, no. 51, pp. 32789–32795, 1996.
[14]
N. Ghoshal, F. García-Sierra, Y. Fu et al., “Tau-66: evidence for a novel tau conformation in Alzheimer's disease,” Journal of Neurochemistry, vol. 77, no. 5, pp. 1372–1385, 2001.
[15]
B. McLaughlin, K. A. Hartnett, J. A. Erhardt et al., “Caspase 3 activation is essential for neuroprotection in preconditioning,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 715–720, 2003.
[16]
A. de Calignon, T. L. Spires-Jones, R. Pitstick, G. A. Carlson, and B. T. Hyman, “Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 7, pp. 757–761, 2009.
[17]
R. Morsch, W. Simon, and P. D. Coleman, “Neurons may live for decades with neurofibrillary tangles,” Journal of Neuropathology and Experimental Neurology, vol. 58, no. 2, pp. 188–197, 1999.
[18]
W. L. Lin, D. W. Dickson, and N. Sahara, “Immunoelectron microscopic and biochemical studies of caspase-cleaved tau in a mouse model of tauopathy,” Journal of Neuropathology and Experimental Neurology, vol. 70, no. 9, pp. 779–787, 2011.
[19]
P. M. Horowitz, K. R. Patterson, A. L. Guillozet-Bongaarts et al., “Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease,” Journal of Neuroscience, vol. 24, no. 36, pp. 7895–7902, 2004.
[20]
H. Guo, S. Albrecht, M. Bourdeau, T. Petzke, C. Bergeron, and A. C. LeBlanc, “Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease,” American Journal of Pathology, vol. 165, no. 2, pp. 523–531, 2004.
[21]
Y. Wang, S. Garg, E. M. Mandelkow, and E. Mandelkow, “Proteolytic processing of tau,” Biochemical Society Transactions, vol. 38, no. 4, pp. 955–961, 2010.
[22]
S. Lee, G. F. Hall, and T. B. Shea, “Potentiation of tau aggregation by cdk5 and GSK3beta,” Journal of Alzheimer's Disease, vol. 26, no. 2, pp. 355–364, 2011.
[23]
A. I. Iliev, S. Ganesan, G. Bunt, and F. S. Wouters, “Removal of pattern-breaking sequences in microtubule binding repeats produces instantaneous tau aggregation and toxicity,” Journal of Biological Chemistry, vol. 281, no. 48, pp. 37195–37204, 2006.
[24]
C. A. Belmokhtar, J. Híllion, and E. Segal-Bendirdjian, “Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms,” Oncogene, vol. 20, no. 26, pp. 3354–3362, 2001.
[25]
A. Fraser and G. Evan, “A license to kill,” Cell, vol. 85, no. 6, pp. 781–784, 1996.
[26]
D. W. Nicholson, A. Ali, N. A. Thornberry et al., “Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis,” Nature, vol. 376, no. 6535, pp. 37–43, 1995.
[27]
K. S. Kosik, L. D. Orecchio, L. Binder, J. Q. Trojanowski, V. M. Y. Lee, and G. Lee, “Epitopes that span the tau molecule are shared with paired helical filaments,” Neuron, vol. 1, no. 9, pp. 817–825, 1988.
[28]
Y. A. Lazebnik, S. H. Kaufmann, S. Desnoyers, G. G. Poirier, and W. C. Earnshaw, “Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE,” Nature, vol. 371, no. 6495, pp. 346–347, 1994.
[29]
C. W. Cotman, W. W. Poon, R. A. Rissman, and M. Blurton-Jones, “The role of caspase cleavage of tau in Alzheimer disease neuropathology,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 2, pp. 104–112, 2005.
[30]
J. H. Cho and G. V. W. Johnson, “Glycogen synthase kinase 3β induces caspase-cleaved tau aggregation in situ,” Journal of Biological Chemistry, vol. 279, no. 52, pp. 54716–54723, 2004.